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The MLV-related retrovirus, XMRV, was recently identiﬁed and reported to be associated with both prostate cancer and chronic
fatigue syndrome. At the National Cancer Institute-Frederick, MD (NCI-Frederick), we developed highly sensitive methods to
detect XMRV nucleic acids, antibodies, and replication competent virus. Analysis of XMRV-spiked samples and/or specimens
from two pigtail macaques experimentally inoculated with 22Rv1 cell-derived XMRV conﬁrmed the ability of the assays used to
detect XMRV RNA and DNA, and culture isolatable virus when present, along with XMRV reactive antibody responses. Using
these assays, we did not detect evidence of XMRV in blood samples (N = 134) or prostate specimens (N = 19) from two
independent cohorts of patients with prostate cancer. Previous studies detected XMRV in prostate tissues. In the present study,
we primarily investigated the levels of XMRV in blood plasma samples collected from patients with prostate cancer. These results
demonstratethatwhileXMRV-relatedassaysdeveloped attheNCI-FrederickcanreadilymeasureXMRVnucleicacids,antibodies,
and replication competent virus, no evidence of XMRV was found in the blood of patients with prostate cancer.
1.Introduction
Xenotropic murine leukemia virus-related virus (XMRV) is
a recently discovered gammaretrovirus reportedly associated
with prostate cancer and chronic fatigue syndrome (CFS) [1,
2].ThediscoveryofXMRVarosefromstudiesinvestigatinga
potential viral cause for diseases in patients with an RNAseL
gene variant. This genotype, which is observed in a varying
subset of patients in cohorts with prostate cancer [1, 3–
8], has been associated with impairment of innate immune
responses to viral infections [5]. Seeking an etiologically
signiﬁcant viral infection associated with impaired RNAse L-
dependent responses, Urisman et al. ﬁrst identiﬁed XMRV
in 2006 in a cohort of prostate cancer patients [2]. The
association of XMRV with prostate cancer, but not its
association with the RNAseL variant, was corroborated by
Schlaberg et al. in 2009 [9]. The prostate cancer studies
were followed by a report from Lombardi et al. presenting
evidence for XMRV infection in 67% of individuals with
severe CFS, compared to 3.7% of healthy individuals [1].
These high reported frequencies of XMRV infection and
putative linkage to a debilitating illness prompted concerns
aboutthepossibilityofanew,widespreadretroviralepidemic
and stimulated additional research towards determining
the prevalence of XMRV infection in diﬀerent populations
worldwide.2 Advances in Virology
Several studies supporting high prevalence of XMRV
infection followed. For example, Arnold et al. detected anti-
XMRV antibodies in 27% of individuals with prostate cancer
[10], Schlaberg et al. found XMRV nucleic acid in 23% of
prostatecancersand4%ofcontrols[11],andDanielsonetal.
detected XMRV in 22.8% of extracted prostate tissues from
individuals who had radical prostatectomies [12]. However,
controversy arose when other laboratories could not demon-
strate comparable ﬁndings in similar cohorts not only in
the US [13]b u ti nG e r m a n y[ 14], The Netherlands [15],
and England [16, 17]. Adding to the controversy, Lo et al.
r e p o r t e dt h ep r e s e n c eo fm o u s er e t r o v i r a ls e q u e n c e s ,b u tn o t
XMRV,in86.5%ofCFSpatients[18].Claimsweremadethat
such ﬁndings supported the association of XMRV infection
with CFS, complicating an already controversial ﬁeld.
Several factors were speculatively proposed to contribute
to the diﬀerential detection of XMRV/MLVs by diﬀerent lab-
oratories. It was suggested that inconsistencies in detection
of XMRV/MLVs in patient samples could result from varied
prevalence of infection in diﬀerent populations, differing
criteriaforpatientselection,anddiﬀeringdetectionmethod-
ologies utilized [19]. It was also proposed that virus levels
may be chronically low or episodic in patient plasma or tis-
sues, making virus detection diﬃcult [19]. Adding to the
complexity, detection of XMRV by PCR is highly susceptible
to false positive results due to the very close genetic re-
lationship of XMRV with endogenous MLVs and the high
prevalence of contaminating mouse genomic DNA in many
specimens [20, 21]. Indeed, studies have suggested that
XMRV detection is the result of laboratory contamination
from infected cell lines [22–25] or contaminated reagents
[26]. Further suggestions of laboratory contamination came
after publication of a study by Paprotka et al. [25], showing
that XMRV originated in a human cancer cell line generated
by passaging prostate cancer cells through immunocompro-
mised mice. This result indicates that XMRV could not have
entered the human population until recently, yet was already
being reported as prevalent in a sizeable fraction of prostatic
cancers. Furthermore, it showed that most “XMRV-speciﬁc”
detection assays could, in fact, detect one or the other of the
two parental proviruses (PreXMRV-1 and 2) that gave rise to
XMRV and are endogenous to some inbred and wild mice.
In assessing this situation, it became clear that to rule out
false positive results and reliably detect XMRV infection, one
must apply several diagnostic methods used in conjunction
with known positive and negative controls.
At the NCI-Frederick, we sought to help clarify the
XMRV controversy by generating multiple assays, including
rigorous methods to measure antibodies to XMRV through
ELISA-based methods, to quantify XMRV proviral DNA and
viral RNA through quantitative PCR and RT-PCR methods,
and to measure infectious virus by viral isolation cultures
using an indicator cell line system. We characterized these
assays using available positive and negative control samples,
including spiked samples and specimens from two pigtail
macaques experimentally inoculated with XMRV. We then
applied these methods to specimens from two cohorts of
prostate cancer patients to determine the levels of XMRV in
their blood. Overall, we observed a high level of concordance
between detection methods and were able to rule out false
positive results by applying multiple assays on the same pa-
tient samples. Applying this approach, we did not ﬁnd ev-
idence of XMRV infection in any of the prostate cancer pa-
tient-derived specimens studied.
2. Methods
2.1. Clinical Prostate Cancer Samples. The XMRV detection
assays developed at the NCI-Frederick were applied to
samples collected from two cohorts of prostate cancer pa-
tients. In total, 134 patients were studied. Plasma samples
from 108 patients were obtained at the UC Davis Cancer
Center. Samples were collected between 2006 and 2010 from
prostatecancerpatientswhowereeithernewlydiagnosed,on
active treatment, or undergoing post-treatment monitoring.
Plasma from all 108 patients was tested for XMRV RNA
and antibodies to CA and TM. Institutional Review Board
(IRB) approval was obtained from the UC Davis Cancer
Center Biorepository, and all study subjects provided written
informed consent.
Samples from an additional 26 recently diagnosed pros-
tate cancer patients were obtained from the Urologic Oncol-
ogy Branch, NIH Clinical Center, Bethesda, MD. All 26
blood samples were tested for the presence of XMRV RNA in
plasma and DNA in whole blood. Tests for XMRV proviral
DNA were also performed on prostate tissue from 19 of
the 26 individuals in this cohort who had radical prosta-
tectomies. Twenty-two of 26 blood samples were tested for
antibodies to CA and TM. A subset of 12 samples was tested
by virus rescue culture including those that had positive
or indeterminate results by X-SCA or ELISA and matched
negativecontrols.ThestudywasapprovedbytheIRBofNCI,
NIH, Bethesda, MD, and all study subjects provided written
informed consent.
2.2. XMRV Nucleic Assay Detection with XMRV Single-Copy
Assays (X-SCA). Similar to the single-copy assay (SCA) for
human immunodeﬁciency virus (HIV) [27], quantitative
real-time PCR and RT-PCR assays for detection of XMRV,
called XMRV single-copy assays (X-SCA), were developed to
quantify XMRV nucleic acid in plasma, whole blood, and
cell suspensions obtained from blood or tissue samples. The
assays were designed using ampliﬁcation primers targeting
a gag leader region conserved between XMRV (as well
as PreXMRV-2 [25] )a n dn o n - X M R Ve n d o g e n o u sM L V s
(forward 5-TGTATCAGTTAACCTACCCGAGT-3 ,r e v e r s e
5-AGACGGGGGCGGGAAGTGTCTC-3 ). Consequently,
eﬃcient ampliﬁcation is achieved from both target templates
allowing detection of either XMRV or MLVs present in
patientsamples.TheTaqmanprobe(5 fam-TGG AGT GGC
TTT GTT GGG GGA CGA- tamra3 ) used for detection
of ampliﬁed products was designed to span a signature
24 nucleotide deletion in the XMRV (PreXMRV-2) gag
leader that diﬀerentiates these from all other MLV sequences
(Figure 1(a)). In the event that a positive sample is identiﬁed
by X-SCA, single-genome sequencing should be performed
to conﬁrm that the source of ampliﬁcation was XMRV andAdvances in Virology 3
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Figure 1: XMRV single-copy assay (X-SCA). X-SCA primers anneal to conserved regions in XMRV/MLV gag leader region while the probe
spans a 24nt deletion in XMRV compared to MLV (a) allowing for diﬀerential ampliﬁcation proﬁles for XMRV and MLV (b). X-SCA
ampliﬁcation products run on a 2% agarose gel distinguish between the products being ampliﬁed since the XMRV product is 24 nt smaller
than the MLV product. Lane 1 is the X-SCA product from the XMRV standard curve, Lane 2 is the MLV product from the genomic DNA
extracted from TA3.Cyc-T1 mouse cells, and Lane 3 is the “no template” negative control (c).
not contaminating mouse DNA with a similar gag deletion,
such as PreXMRV-2.
XMRV RNA was extracted from plasma samples follow-
ing ultracentrifugation exactly as described for HIV SCA
[27] and genomic DNA was extracted and whole blood
samples using the Promega genomic DNA Extraction Kit
(Cat no. A1120) according to the manufacturer’s suggested
protocol. Reaction conditions for synthesizing cDNA and
measuring RNA copy number were exactly as described
previously for HIV SCA [27]. XMRV proviral copy number
wasdeterminedusingtheLightcycler480ProbesMaster(Cat
no. 04707494001) according to protocol and by performing
45 cycles of 95◦C for 15 seconds, 60◦Cf o r1m i n u t ea f t e ra n
initial 10 minute, 95◦C polymerase activation step. Accurate
detection of XMRV by X-SCA was veriﬁed by testing spiked
human blood products [28] and by testing blood samples
collected from XMRV inoculated macaques (Del Prete et
al., in preparation). Pigtail macaques were experimentally
inoculated with XMRV (∼4.8 × 109 RNA copy equivalents)
prepared from the supernatant of 22Rv1 cells (Lot SP1592,
Biological Products Core, AIDS and Cancer Virus Program,
SAIC-Frederick, Inc, NCI-Frederick). Plasma and PBMC
samples were collected prior to inoculation and through
119 days after inoculation. These pre- and post-inoculation
specimens were used as reference control samples in eval-
uating X-SCA methods for detection of XMRV. Details of
the macaque infection study will be reported elsewhere (Del
Prete et al. in preparation). Animals were housed and
cared for in accordance with American Association for Ac-
creditation of Laboratory Animal Care (AALAC) standards
in an AAALAC accredited facility, and all animal proce-
dures were performed according to a protocol approved by
the Institutional Animal Care and Use Committee of the
NationalCancerInstitute.DetectionofMLVwasqualiﬁedby
extractingmousegenomicDNAfromTA3.Cyc-T1cellsusing
the Promega genomic DNA Extraction Kit (Cat no. A1120)
and performing X-SCA in duplicate on dilutions of 3000 to
0.03 cell equivalents.4 Advances in Virology
All patient samples were tested by X-SCA in duplicate
or triplicate with equal numbers of no template controls
(NTC) to monitor the level of false positives due to either
viral or mouse genomic DNA contamination. The level of
detection for XMRV nucleic acid in clinical samples was
determined by the volume of sample available for testing
(100µL to 3mL). Therefore, X-SCA sensitivity varied from
0.6 to 20.6copies/mL of plasma and 0.9–10copies/mL in
whole blood. Because of the high frequency of false positives
due to contaminating mouse DNA, we set strict criteria for
declaring a sample positive for XMRV, requiring detection
of viral sequence in all replicate PCR reactions from the
samples being tested. These criteria result in a minimum
detection of 1.8–41.2copies XMRV RNA/mL in plasma and
2.7–30copies XMRV DNA/mL in whole blood for a positive
X-SCAtest,dependingonthevolumeofsamplebeingtested.
If discordant results are obtained from duplicate or triplicate
wells, then the result is considered indeterminate and is
repeated where suﬃcient sample is available.
2.3. XMRV Serology. XMRV antigens were prepared in the
Protein Expression Laboratory, SAIC-Frederick, MD, as pre-
viously described [29]. Puriﬁed XMRV antigens were used
to develop and optimize ELISA-based protocols (Bagni et al.,
in preparation). Brieﬂy, puriﬁed CA and TM were spotted
onto Meso Scale Discovery (MSD) (Gaithersburg, MD)
standard 96-well plates at 8µg/mL and 2µg/mL, respectively.
Samples were diluted 1:100 and incubated with individual
XMRV antigens. Human antibodies were detected using
biotin labeled anti-human IgG (Jackson ImmunoResearch,
West Grove, Pa) and MSD-proprietary Sulfo-tagged strep-
tavidin detection reagent and read on a SECTOR Imager
6000 (MSD) plate reader. The XMRV serology assays were
qualiﬁedwithsamplesobtainedfromXMRV-inoculatedma-
caques(DelPreteetal.,inpreparation).Patientsampleswere
considered reactive if the MSD electrochemiluminescent
signal (ECL)wasat least50% relative to theECL signal of the
macaque positive control sera. Less reactive patient samples
that were at least 2 standard deviations above the average
negative human sample were considered indeterminate.
2.4. XMRV Culture Detection. The presence of replication-
competentXMR Vwasdeterminedinavirusrescuecoculture
assay using indicator cells designated DERSE (Detectors of
Exogenous Retroviral Sequence Elements) and using expres-
sionofaGFPreporterasthereadout.DERSE.LiGPcellsarea
subcloneofLNCaPcells(giftfromDr.FrancisRuscetti,NCI)
stably transfected with pBabe.iGFP-puro and screened for
susceptibility to XMRV infection (Lee et al., in preparation).
pBabe.iGFP-puro is an MLV proviral vector that encodes an
intron-interrupted reporter GFP gene and is only expressed
after mobilization by an infecting gammaretrovirus for a
second round of infection of DERSE.LiGP cells. Similar MLV
vectors that only express a reporter after being propagated in
infection have been described previously using HEK293 cells
[30]. The DERSE.LiGP assay will detect any MLV-related
viruses that are capable of replicating in human prostate
cancer cells. Virus replication can be detected by monitoring
GFP-positivecellseitherbyﬂuorescencemicroscopyorFACS
analysis.
DERSE.LiGP indicator cells were maintained in Roswell
Park Memorial Institute (RPMI) media 1640 (Invitrogen)
supplementedwith15%fetalbovineserum(FBS)(Hyclone),
1x Pen/Strep/Glutamine (100U/mL Penicillin, 0.1mg/mL
Streptomycin, and 0.292mg/mL Glutamine, Invitrogen) and
1µg/mL puromycin (Calbiochem). DERSE.LiGP cells were
plated at 1 × 105 cells/well in a 24-well tissue culture plate
one day before infection. As a positive control, 22Rv1 cell
supernatants were diluted in RPMI media and added to
cells the next day in the presence of 5µg/mL of polybrene
[31]. Culture medium was refreshed the following day by
replacement or splitting cells at a 1:3 ratio depending on cell
density. Although GFP can be detected in positive control
samples within 3 days of infection, to maximize sensitivity
fordetectionoflowlevelsofvirus,DERSE.LiGPcellsexposed
to clinical specimens were maintained in culture for at least
two weeks and observed at intervals by ﬂuorescence mi-
croscopy. After two weeks, cells were resuspended in a
2% paraformaldehyde (PFA) solution and GFP expression
was measured by FACS (FACSCalibur, Becton Dickinson),
indicative of a spreading infection. While DERSE.LiGP
cells are relatively insensitive to heparin, plasma samples
containing EDTA are toxic to the cultures. To mitigate
toxicity, 200µL of EDTA containing plasma samples were
distributed into Eppendorf tubes in the presence of 7.5mM
CaCl2 to neutralize the EDTA and 30U/mL heparin salt to
minimize sample clotting. Tubes were incubated for 4hrs at
4◦C to separate the plasma from residual clotting. Accurate
detection of XMRV by virus culture was veriﬁed using a
dilution series of supernatants from 22Rv1 cells and XMRV-
spiked human plasma samples containing approximately 107
to 10 copies of XMRV RNA. Using XMRV-spiked samples,
we noted a loss of detection sensitivity of three- to ﬁvefold
in EDTA containing plasma samples treated in the above
manner. A recent report of XMRV inactivation by human
complement may explain in part the loss of infectivity
after addition of plasma [24]. Prostate cancer samples with
indeterminate resultsby X-SCA or ELISAwerematched with
negativesamplesandtestedblindedintheviruscultureassay.
We required that samples test positive for XMRV nucleic
acid (RNA or DNA) and by at least one other detect method
(immunoassay or culture assay) to be declared positive for
XMRV infection.
All reagents developed at the NCI-Frederick and de-
scribed here are being made available to the extramural
research community through the NIH AIDS Research and
Reference Reagent Program or AIDS and Cancer Virus
Program, SAIC-Frederick, Inc., National Cancer Institute,
Frederick.
3. Results
3.1. Diﬀerentiating between XMRV and MLV with X-SCA
Probe. The X-SCA probe used for detection of ampliﬁed
products spans a signature 24 nucleotide deletion in the
XMRV [1] and in the PreXMRV-2 [32] gag leader thatAdvances in Virology 5
diﬀerentiates these from all other MLV sequences (Fig-
ure 1(a)). Ampliﬁcations of XMRV from 22Rv1 DNA and
MLV from mouse genomic DNA (extracted from TA3.CycT1
cells) show that the probe design results in a lower level
of plateau ﬂuorescence from non-XMRV MLV templates
t h a nf r o mX M R Vt e m p l a t e s( F i g u r e1(b)), likely due to
ineﬃcient binding and/or degradation of the probe during
MLV extension compared to XMRV extension. The result
of the probe design is diﬀerential ampliﬁcation proﬁles for
XMRV and MLV, indicating which product is being detected
in the assay and the proportions of each if both templates are
detected. To conﬁrm the result, the products were run on an
agarose gel (Figure 1(c)). The XMRV X-SCA product is 86nt
long and the MLV product 110nt, easily distinguishable on a
2% agarose gel.
3.2. Qualifying XMRV Assay Detection Capabilities with
Spiked Human Samples. Assays for detection of XMRV nu-
cleic acid and replication-competent virus were established
using XMRV-spiked samples as positive control specimens.
To determine the accuracy and sensitivity of X-SCA methods
to detect XMRV in human blood products, we tested a full
panel of plasma and whole blood samples that were spiked
or not spiked with XMRV derived from 22Rv1 cells. The
panel was blinded as to which samples were XMRV positive
a n dw h i c hw e r eX M R Vn e g a t i v ea n dw e r ep r o v i d e dt o
us by the XMRV Scientiﬁc Research Working Group for
testing by X-SCA [28]. Results from the blinded panel of
spiked samples were described previously by Simmons et al.
[28] and demonstrated that we detected XMRV RNA and
proviral DNA using X-SCA with 100% accuracy. The level
of sensitivity for detecting XMRV RNA in the spiked plasma
panel was limited by the volume of sample tested for XMRV
(270µL) to 3.3 RNA copies/mL. The level of sensitivity for
detecting XMRV proviral DNA was a single XMRV-infected
22Rv1 cell in whole blood samples. All unspiked samples
were properly reported as negative for XMRV detection
indicating a very low rate of false positivity.
The use of DERSE.L-iG-P cells to detect XMRV was ver-
iﬁed using 22Rv1 culture supernatants and XMRV-spiked
human plasma. Figure 2 shows the results from virus rescue
experiments performed under the following conditions (i)
22Rv1 supernatant alone, (ii) 22Rv1 supernatant treated
with CaCl2 and heparin, (iii) 22Rv1 supernatant spiked into
humanplasmatreatedwithCaCl2 andheparin.DERSE.LiGP
cells treated with EDTA-containing human plasma alone
are not viable. Proportions of GFP-positive cells detected
by FACS at day 4 and day 8 after infection are shown in
Figures 2(a) and 2(b). DERSE.LiGP cells exposed to 0.01µL
of 22Rv1 supernatant were GFP-positive by microscopy
within 4 days of infection (Figure 2) demonstrating the
sensitivityofthisassayfordetectionofreplicationcompetent
XMRV. The sensitivity of this detection decreased 3–5-fold
in the presence of EDTA-containing plasma samples treated
as described above. This decrease could in part be due to
the presence of human complement as has been recently
reported [24]. Additional days of culture increased the
numberofGFP-positivecellsexposedtovirusinthepresence
Table 1: X-SCA Results on XMRV-inoculated macaques.
Monkey ID Days after
inoculation
Plasma XMRV
RNA copies/mL
Copies of
XMRV DNA per
106 PBMCs
14232 0 <1.1 0
14232 5 534.11 197
14232 119 <1.1 23
8242 0 <1.1 0
8242 13 2153.56 2833
8242 119 <1.1 645
Table 2: Immunoassay of plasma from XMRV-inoculated maca-
ques.
Monkey ID Days after inoculation Reactivity with
CA TM
8242 0 19.5 248.5
8242 76 12713 544405
14232 0 14.5 145
14232 76 20108 285277
or absence of plasma. For this reason, cultures infected with
human specimens were carried out for a minimum of two
weeks.
3.3. Verifying Assay Detection Capabilities with Blood Samples
from XMRV-Inoculated Macaques. To validate the speciﬁcity
of X-SCA and ELISA, we used specimens from two pigtail
macaques experimentally inoculated with XMRV. Detailed
results from the macaque study will be reported elsewhere
(Del Prete et al., in preparation). In short, samples tested
by X-SCA revealed that peak viremia was achieved at 5
days after inoculation in one animal and at 13 days in
the second (Table 1). By day 28, levels of XMRV RNA
in plasma had declined to <1copy/mL in both animals.
PBMC-associatedXMRVDNAwasalsomeasuredbyX-SCA.
DNA levels peaked with similar kinetics as plasma viremia
but persisted with levels of 23 and 645copies/106 PBMC
in the two animals, respectively, at the end of the follow-
up period, 119 days after inoculation. Antibody reactivity
to XMRV capsid (CA) and transmembrane protein (TM)
measured by ELISA was undetectable prior to inoculation
but were robustly positive thereafter (Table 2)( D e lP r e t ee t
al., in preparation). Replication competent XMRV cannot
be cultured from macaque plasma or PBMC samples due
to extensive hypermutation of the provirus post-inoculation,
likely due to the eﬀect of APOBEC proteins (Del Prete et al.,
inpreparation).Consequently,XMRV-spikedhumanplasma
was used to verify the DERSE.L-iG-P cells for detection of
XMRV.
3.4. Testing Prostate Cancer Samples for XMRV Nucleic Acid,
Antibodies, and Isolatable Virus. Samples obtained from the
two cohorts of prostate cancer patients were assayed ﬁrst
for XMRV nucleic acid (X-SCA) and antibody reactivity
against XMRV CA and TM protein (Tables 3 and 4). No6 Advances in Virology
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Figure 2: Verifying XMRV rescue by culturing on DERSE cells with 22Rv1 supernatants and with XMRV-spiked human plasma. XMRV
culturing under the following conditions: (i) 22Rv1 supernatant alone (black bars), (ii) 22Rv1 supernatant treated with CaCl2 +h e p a r i n
(white bars), (iii) 22Rv1 supernatant spiked into human plasma treated with CaCl2 + heparin (gray bars). GFP-positive cells were analyzed
by FACS at day 4 (a) and day 8 (b).
plasma or prostate tissue samples in the NIH prostate cancer
cohort or the UC Davis prostate cancer cohort were positive
for XMRV nucleic acids or antibodies (Tables 3 and 4).
However, two plasma samples in the NIH cohort (0594,
0771) were indeterminate for XMRV RNA. One of these
samples (0594) was negative by ELISA, and the other (0771)
hadanindeterminateELISAresult.Oneotherpatientsample
in the NIH cohort (0781) was indeterminate for XMRV
antibody reactivity but negative for XMRV nucleic acid
(Table 3). All three of these samples, along with 9 matched
negative samples, were blinded and tested for replicating
virus using the DERSE.L-iG-P assay. Virus could not be
cultured from any of these plasma samples while it was read-
ily recovered from positive control samples (22Rv1-derived
XMRV spiked into negative human plasma) (Figure 3).
Consequently, by our prospectively deﬁned criteria, none of
the 26 patient samples in the NIH cohort were considered
to be XMRV infected (positive for nucleic acid, antibody,
and/orreplicationcompetentvirus)(Table3).All108plasma
samples from prostate cancer patients obtained from UC
D a vi sw e r ea s s a y e df o rX M R VR N Aa n da n t i b o d i e s( T a b l e4).
All samples were negative for XMRV nucleic acid except one
(0739), which was indeterminate. No sample was found to
be antibody reactive by our ELISA criteria (at least 50%
reactiverelative tothe macaquepositive controlsera).Twelve
of the 108 samples were indeterminate for XMRV reactivity
to either CA or TM (2 standard deviations above the average
negative human sample) but were negative for nucleic acid
(Table 4). No sample was indeterminate or positive for both
XMRV nucleic acid and antibody, and therefore, all were
determined to be negative for XMRV infection.
4. Discussion
After publication of the XMRV study by Lombardi et al. in
October 2009 suggesting a possible disease association with
CFS and a surprisingly high apparent seroprevalence for
XMRV even among healthy control subjects, researchers at
the NCI-Frederick set out to develop rigorous methods to
evaluate the prevalence of XMRV infection. Using control
samples, including spiked specimens where appropriate, we
developed assays to measure plasma XMRV RNA viremia,
cell-associated XMRV DNA levels, and antibodies to XMRV
CA and TM. Because Lombardi et al. reported the presence
of culture rescuable replication-competent virus from the
bloodofstudysubjectsusingcoculturewithahumancellline
(LNCap), we created DERSE cells, derivatives of the same
LNCap cells with a ﬂuorescent reporter to detect XMRV
replication. These cells broadly and sensitively detect the
replication of diﬀerent MLV-related gammaretroviruses that
exhibit a tropism for human prostate cancer cells. In the
absence of patient-derived deﬁnitive positive and negative
control specimens, we applied our diﬀerent assay methods
to samples obtained from two pigtail macaques prior to
and after experimental XMRV inoculation. XMRV plasma
viremia was detectable in both inoculated macaques for 2-
3 weeks after inoculation but then declined to undetectable
levels (Del Prete et al., in preparation). However, XMRV
DNA in PBMCs and serum antibodies remained at readily
measurable levels for the duration of study follow-up in
both animals (Del Prete et al., in preparation). Evaluation
of samples from the inoculated macaques demonstrated the
ability of our methods to reliably detect evidence of XMRV
infection in blood samples and showed that XMRV provirus
and antibodies persist even when viremia is not detectable.
In the development of diagnostic tools for XMRV in-
fection, it became clear that a single method for XMRV
detection would not be suﬃcient for deﬁnitive diagnosis due
to a high frequency of false positives by PCR from contam-
inating nucleic acids (especially mouse genomic DNA) and
high background reactivity seen by ELISA, even in samplesAdvances in Virology 7
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Figure 3:TestingplasmasamplesfromprostatecancerpatientsforreplicationcompetentXMRV.TwelvesampleswereblindedastotheirX-SCA
and ELISA results and were tested for replicating virus using the DERSE.L-iG-P assay in two separate experiments. Six samples were tested
in experiment 1 at passages 10, 13, 17, and 22 (a). All passages were negative for XMRV while virus was recovered from the positive control
samples (107 copies of XMRV from 22Rv1 cells spiked into human plasma). Six additional samples were tested in experiment 2 at passages
6, 9, and 16 (b). All passages were negative for XMRV while virus was recovered from the positive control samples.8 Advances in Virology
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Table 4: X-SCA and ELISA results on prostate cancer samples from UC-Davis cohort.
Plasma RNA Plasma RNA
Patient ID Copies/mL ELISA result Overall result Patient ID Copies/mL ELISA result Overall result
P0005 <16.5 Indeterminate NEGATIVE P0566 <16.5 NR NEGATIVE
P0013 <16.5 NR NEGATIVE P0572 <16.5 NR NEGATIVE
P0015 <16.5 NR NEGATIVE P0592 <16.5 NR NEGATIVE
P0024 <16.5 NR NEGATIVE P0593 <16.5 NR NEGATIVE
P0026 <16.5 NR NEGATIVE P0605 <16.5 NR NEGATIVE
P0027 <16.5 NR NEGATIVE P0611 <16.5 NR NEGATIVE
P0031 <16.5 NR NEGATIVE P0612 <16.5 NR NEGATIVE
P0034 <16.5 NR NEGATIVE P0617 <16.5 NR NEGATIVE
P0036 <16.5 NR NEGATIVE P0632 <16.5 NR NEGATIVE
P0044 <16.5 NR NEGATIVE P0637 <16.5 NR NEGATIVE
P0045 <16.5 NR NEGATIVE P0641 <16.5 NR NEGATIVE
P0118 <16.5 NR NEGATIVE P0650 <16.5 NR NEGATIVE
P0133 <16.5 NR NEGATIVE P0657 <16.5 Indeterminate NEGATIVE
P0144 <16.5 NR NEGATIVE P0659 <16.5 NR NEGATIVE
P0154 <16.5 NR NEGATIVE P0672 <16.5 NR NEGATIVE
P0156 <16.5 NR NEGATIVE P0673 <16.5 NR NEGATIVE
P0162 <16.5 Indeterminate NEGATIVE P0675 <16.5 NR NEGATIVE
P0167 <16.5 NR NEGATIVE P0679 <16.5 NR NEGATIVE
P0170 <16.5 NR NEGATIVE P0685 <16.5 NR NEGATIVE
P0172 <16.5 NR NEGATIVE P0710 <16.5 NR NEGATIVE
P0177 <16.5 NR NEGATIVE P0721 <16.5 NR NEGATIVE
P0185 <16.5 NR NEGATIVE P0723 <20.6 NR NEGATIVE
P0195 <16.5 Indeterminate NEGATIVE P0726 <16.5 Indeterminate NEGATIVE
P0209 <16.5 NR NEGATIVE P0733 <16.5 NR NEGATIVE
P0219 <16.5 Indeterminate NEGATIVE P0739 55 NR NEGATIVE
P0232 <16.5 NR NEGATIVE P0766 <20.6 NR NEGATIVE
P0239 <16.5 NR NEGATIVE P0778 <16.5 NR NEGATIVE
P0293 <16.5 NR NEGATIVE P0787 <16.5 NR NEGATIVE
P0306 <16.5 NR NEGATIVE P0792 <16.5 NR NEGATIVE
P0314 <16.5 NR NEGATIVE P0826 <16.5 NR NEGATIVE
P0321 <16.5 NR NEGATIVE P0846 <16.5 NR NEGATIVE
P0322 <16.5 NR NEGATIVE P0848 <16.5 NR NEGATIVE
P0325 <16.5 NR NEGATIVE P0852 <20.6 NR NEGATIVE
P0327 <16.5 NR NEGATIVE P0906 <16.5 Indeterminate NEGATIVE
P0332 <16.5 Indeterminate NEGATIVE P0916 <16.5 NR NEGATIVE
P0340 <16.5 Indeterminate NEGATIVE P0923 <16.5 NR NEGATIVE
P0342 <16.5 NR NEGATIVE P0952 <16.5 NR NEGATIVE
P0346 <16.5 Indeterminate NEGATIVE P0984 <16.5 NR NEGATIVE
P0348 <16.5 NR NEGATIVE P0989 <16.5 NR NEGATIVE
P0351 <16.5 NR NEGATIVE P0996 <16.5 NR NEGATIVE
P0355 <16.5 NR NEGATIVE P0999 <16.5 NR NEGATIVE
P0366 <20.6 NR NEGATIVE P1010 <16.5 NR NEGATIVE
P0380 <16.5 NR NEGATIVE P1025 <16.5 NR NEGATIVE
P0382 <16.5 NR NEGATIVE P1032 <16.5 NR NEGATIVE
P0384 <16.5 NR NEGATIVE P1063 <16.5 NR NEGATIVE10 Advances in Virology
Table 4: Continued.
Plasma RNA Plasma RNA
Patient ID Copies/mL ELISA result Overall result Patient ID Copies/mL ELISA result Overall result
P0388 <16.5 NR NEGATIVE P1076 <16.5 NR NEGATIVE
P0509 <16.5 Indeterminate NEGATIVE P1086 <16.5 NR NEGATIVE
P0511 <16.5 NR NEGATIVE P1108 <16.5 Indeterminate NEGATIVE
P0530 <16.5 NR NEGATIVE P1110 <16.5 NR NEGATIVE
P0532 <16.5 NR NEGATIVE P1211 <16.5 NR NEGATIVE
P0535 <16.5 NR NEGATIVE P1268 <16.5 NR NEGATIVE
P0536 <16.5 NR NEGATIVE P1297 <16.5 NR NEGATIVE
P0544 <16.5 NR NEGATIVE P1304 <16.5 NR NEGATIVE
P0562 <16.5 NR NEGATIVE P1318 <16.5 NR NEGATIVE
from healthy control subjects, presumably reﬂecting cross-
reactivity. Therefore, we suggest a multiple assay approach
to determine the XMRV status of patient samples. We estab-
lished diagnostic criteria requiring that all replicates from
X-SCA analysis must be positive and that serum antibodies
and/or replicating virus must also be detectable in the
same patient in order to report the patient XMRV positive.
Samples resulting in discordant results from PCR replicates
are reported as indeterminate. Despite earlier reports that
evidence of XMRV infection was detected in as many as 20%
of prostate tumors [2, 10–12], using the assays we developed,
we did not ﬁnd clear evidence for XMRV in the blood of
two independent cohorts of patients with prostate cancer
(total n = 134) or in the prostate tissue of a small subset
of these individuals (n = 19). Based on previously reported
frequencies of XMRV detection in prostate cancer patients,
if XMRV is present in the blood of infected individuals,
we expected that approximately 27 of the 134 patients in
our study would be positive for XMRV. One patient from
the NIH cohort (0771) had an indeterminate X-SCA result
(2/3 reactions were positive for RNA). This sample was also
positive for reactivity to CA and TM by ELISA. However, no
XMRV DNA was found in the whole blood from this patient,
and replication competent virus could not be recovered from
the sample. Taken together, these data are considered an
indeterminate result by our criteria. No other samples were
positive by more than one diagnostic method.
The occasional positive X-SCA reaction is not above
background for this assay. We regularly run 96-well plates of
“no template controls” using both our X-SCA primers and
primers targeting intracisternal A particles (IAP) [20, 21, 33]
that are present in high copies in the mouse genome in order
to monitor the levels of contaminating mouse DNA in the
reagents and in the environment. We have found that about
5% of wells are positive with the X-SCA primers and about
20% with the IAP primers. Based on these backgrounds, we
expect to detect low levels of mouse DNA contamination in
samples tested, as seen is this study and in others [20, 21, 33].
Therefore, we required that all replicates of patient samples
be positive to obtain a “positive” X-SCA result. We did not
test the samples directly with IAP primers since we have not
successfully found reagents and an environment that are free
from mouse genomic DNA (on average about 1/3000 of a
mouse genome per PCR reaction).
Although we had an occasional indeterminate result
for XMRV RNA in the plasma samples studied, we did
not detect XMRV DNA in any sample tested, despite the
ability of our assay to sensitively detect XMRV DNA in
spiked control samples and in specimens from inoculated
macaques [28] (Del Prete et al., in preparation). Results
from the inoculated macaques showed that in experimental
infection, XMRV proviral DNA is readily measurable in
blood cells even when plasma viremia was not detectable
(Del Prete et al., in preparation), further suggesting that
these patients do not carry XMRV in their blood. Findings
frompreviousstudiesreportinghigherprevalenceforXMRV
in similar cohorts [2, 11, 12] typically involved testing of
prostatetumors.Noneofthesestudiesreportedthedetection
of XMRV in blood samples or the isolation of infectious
virus from clinical specimens, and only one measured the
presenceofreactiveantibodiesthroughavirusneutralization
assay [10]. Detection of antibody responses to speciﬁc viral
proteins by ELISA or by reactivity to XMRV immunoblots
was not assessed. If we had used less rigorous criteria basing
an overall diagnosis on a single, nonconﬁrmed test and not
requiring all replicates to yield the same result, then our two
cohortswouldhavegivenrisetoanapparent,andinourview
almost certainly incorrect, reported XMRV prevalence rate
of approximately 12%. These considerations may explain
conﬂicting prior reports for the prevalence of XMRV and
are consistent with claims that XMRV detection is likely
the result of laboratory contamination [22, 26, 33, 34]. Par-
ticularly given the potential for false positive results in PCR
and serological assays for XMRV, our results suggest that
applying multiple diagnostic methods including measuring
levels of proviral DNA in blood cells provides a more
reliable approach for investigating the prevalence of XMRV.
These results also demonstrate that XMRV nucleic acid, and
antibodies are undetectable in the blood of patients with
prostate cancer.Advances in Virology 11
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